Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Targeting cysteine proteases in trypanosomatid disease drug discovery

Texto completo
Autor(es):
Ferreira, Leonardo G. [1] ; Andricopulo, Adriano D. [1]
Número total de Autores: 2
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Pesquisa & Inovacao Biodiversidade & Farmacos, Lab Quim Med & Computac, Ave Joao Dagnone 1100, BR-13563120 Sao Carlos, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo de Revisão
Fonte: PHARMACOLOGY & THERAPEUTICS; v. 180, p. 49-61, DEC 2017.
Citações Web of Science: 8
Resumo

Chagas disease and human African trypanosomiasis are endemic conditions in Latin America and Africa, respectively, for which no effective and safe therapy is available. Efforts in drug discovery have focused on several enzymes from these protozoans, among which cysteine proteases have been validated as molecular targets for pharmacological intervention. These enzymes are expressed during the entire life cycle of trypanosomatid parasites and are essential to many biological processes, including infectivity to the human host. As a result of advances in the knowledge of the structural aspects of cysteine proteases and their role in disease physiopathology, inhibition of these enzymes by small molecules has been demonstrated to be a worthwhile approach to trypanosomatid drug research. This review provides an update on drug discovery strategies targeting the cysteine peptidases cruzain from Trypanosoma cruzi and rhodesain and cathepsin B from Trypanosoma brucei. Given that current chemotherapy for Chagas disease and human African trypanosomiasis has several drawbacks, cysteine proteases will continue to be actively pursued as valuable molecular targets in trypanosomatid disease drug discovery efforts. (C) 2017 Published by Elsevier Inc. (AU)

Processo FAPESP: 13/07600-3 - CIBFar - Centro de Inovação em Biodiversidade e Fármacos
Beneficiário:Glaucius Oliva
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
Processo FAPESP: 13/25658-9 - Planejamento e desenvolvimento de candidatos a fármacos para a Doença de Chagas
Beneficiário:Leonardo Luiz Gomes Ferreira
Linha de fomento: Bolsas no Brasil - Pós-Doutorado